Tempus AI: Data And Applications Will Unlock More Upside (NASDAQ:TEM)
· seekingalpha.com
Tempus AI's Q2 oncology testing volumes grew 31% YoY, with MRD test volumes nearly doubling since Q4 2025. Read why TEM stock is a Buy.
Back in July, I provided an update on Tempus AI, Inc. ( TEM ) after their Personalis ( PSNL ) acquisition announcement. Despite being a little expensive, I view...